Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field - PubMed (original) (raw)
Review
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field
Shuji Ogino et al. Gut. 2011 Mar.
Abstract
Colorectal cancer is a complex disease resulting from somatic genetic and epigenetic alterations, including locus-specific CpG island methylation and global DNA or LINE-1 hypomethylation. Global molecular characteristics such as microsatellite instability (MSI), CpG island methylator phenotype (CIMP), global DNA hypomethylation, and chromosomal instability cause alterations of gene function on a genome-wide scale. Activation of oncogenes including KRAS, BRAF and PIK3CA affects intracellular signalling pathways and has been associated with CIMP and MSI. Traditional epidemiology research has investigated various factors in relation to an overall risk of colon and/or rectal cancer. However, colorectal cancers comprise a heterogeneous group of diseases with different sets of genetic and epigenetic alterations. To better understand how a particular exposure influences the carcinogenic and pathologic process, somatic molecular changes and tumour biomarkers have been studied in relation to the exposure of interest. Moreover, an investigation of interactive effects of tumour molecular changes and the exposures of interest on tumour behaviour (prognosis or clinical outcome) can lead to a better understanding of tumour molecular changes, which may be prognostic or predictive tissue biomarkers. These new research efforts represent 'molecular pathologic epidemiology', which is a multidisciplinary field of investigations of the inter-relationship between exogenous and endogenous (eg, genetic) factors, tumoural molecular signatures and tumour progression. Furthermore, integrating genome-wide association studies (GWAS) with molecular pathological investigation is a promising area (GWAS-MPE approach). Examining the relationship between susceptibility alleles identified by GWAS and specific molecular alterations can help elucidate the function of these alleles and provide insights into whether susceptibility alleles are truly causal. Although there are challenges, molecular pathological epidemiology has unique strengths, and can provide insights into the pathogenic process and help optimise personalised prevention and therapy. In this review, we overview this relatively new field of research and discuss measures to overcome challenges and move this field forward.
Conflict of interest statement
Competing interest: None to declare.
Figures
Figure 1
Illustration of traditional epidemiology (A), traditional molecular pathology (B), and molecular pathologic epidemiology (C). Note that molecular pathology plays a central role in molecular pathologic epidemiology. Molecular pathologic epidemiology addresses a question whether a particular exposure factor is associated with a specific molecular change in colorectal cancer (C, left side), as well as a question whether a specific molecular change can interact with a particular exposure factor to affect tumor cell behavior (C, right side). The latter represents a new direction of molecular pathologic epidemiology where results can provide additional insights on mechanism of how the tumoral molecular change and the exposure factor of interest influence tumor cell behavior. CRC, colorectal cancer.
Figure 2
Comparison of a case-case study design (A), a case-control study design (B) and a prospective cohort study design (C). Smoking status is used as an example of an exposure variable, and KRAS mutation status in colorectal cancer as an outcome variable. See detailed explanations in text. CRC, colorectal cancer.
Similar articles
- Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
Wielandt AM, Hurtado C, Moreno C M, Villarroel C, Castro M, Estay M, Simian D, Martinez M, Vial MT, Kronberg U, López-Köstner F. Wielandt AM, et al. Tumour Biol. 2020 Jul;42(7):1010428320938492. doi: 10.1177/1010428320938492. Tumour Biol. 2020. PMID: 32635826 - LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS. Ogino S, et al. Int J Cancer. 2008 Jun 15;122(12):2767-73. doi: 10.1002/ijc.23470. Int J Cancer. 2008. PMID: 18366060 Free PMC article. - Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.
Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Ogino S, et al. Mod Pathol. 2013 Apr;26(4):465-84. doi: 10.1038/modpathol.2012.214. Epub 2013 Jan 11. Mod Pathol. 2013. PMID: 23307060 Free PMC article. Review. - Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, DeJulius KL, Manilich E, Church JM, Casey G, Kalady MF. Sanchez JA, et al. Br J Surg. 2009 Oct;96(10):1196-204. doi: 10.1002/bjs.6683. Br J Surg. 2009. PMID: 19787768 - Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Ogino S, et al. Oncogene. 2014 Jun 5;33(23):2949-55. doi: 10.1038/onc.2013.244. Epub 2013 Jun 24. Oncogene. 2014. PMID: 23792451 Free PMC article. Review.
Cited by
- MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer.
Dou R, Nishihara R, Cao Y, Hamada T, Mima K, Masuda A, Masugi Y, Shi Y, Gu M, Li W, da Silva A, Nosho K, Zhang X, Meyerhardt JA, Giovannucci EL, Chan AT, Fuchs CS, Qian ZR, Ogino S. Dou R, et al. Cancer Immunol Res. 2016 Nov;4(11):927-935. doi: 10.1158/2326-6066.CIR-16-0112. Epub 2016 Oct 13. Cancer Immunol Res. 2016. PMID: 27737877 Free PMC article. - Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality.
Mehta RS, Chong DQ, Song M, Meyerhardt JA, Ng K, Nishihara R, Qian Z, Morikawa T, Wu K, Giovannucci EL, Fuchs CS, Ogino S, Chan AT. Mehta RS, et al. Gastroenterology. 2015 Sep;149(3):614-22. doi: 10.1053/j.gastro.2015.05.038. Epub 2015 May 27. Gastroenterology. 2015. PMID: 26026393 Free PMC article. - Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Li W, et al. BMC Cancer. 2015 May 1;15:340. doi: 10.1186/s12885-015-1345-3. BMC Cancer. 2015. PMID: 25929517 Free PMC article. - Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study.
Andersen V, Egeberg R, Tjønneland A, Vogel U. Andersen V, et al. BMC Cancer. 2012 May 17;12:183. doi: 10.1186/1471-2407-12-183. BMC Cancer. 2012. PMID: 22594912 Free PMC article. - Commentary: Lifestyle factors and colorectal cancer microsatellite instability--molecular pathological epidemiology science, based on unique tumour principle.
Ogino S, Giovannucci E. Ogino S, et al. Int J Epidemiol. 2012 Aug;41(4):1072-4. doi: 10.1093/ije/dys076. Epub 2012 May 16. Int J Epidemiol. 2012. PMID: 22596930 Free PMC article. No abstract available.
References
- Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32. - PubMed
- Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–70. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 CA151993-01/CA/NCI NIH HHS/United States
- P01 CA055075-17/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- K07 CA122826-03/CA/NCI NIH HHS/United States
- P50 CA127003-03/CA/NCI NIH HHS/United States
- P50 CA127003/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 CA151993/CA/NCI NIH HHS/United States
- K07 CA122826/CA/NCI NIH HHS/United States
- R01 CA137178/CA/NCI NIH HHS/United States
- P01 CA87969/CA/NCI NIH HHS/United States
- R01 CA137178-02/CA/NCI NIH HHS/United States
- P01 CA55075/CA/NCI NIH HHS/United States
- P01 CA087969-09/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous